ArticleJournal of cancer research and clinical oncology2026
Safety and efficacy of nab-paclitaxel combined with nedaplatin and bevacizumab in patients with platinum-resistant epithelial ovarian cancer: a retrospective cohort study.
Article in Journal of cancer research and clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
Abstract
purposeTo evaluate the safety and efficacy of nab-paclitaxel combined with nedaplatin and bevacizumab in patients with platinum-resistant epithelial ovarian cancer (PROC).
methodsWe enrolled PROC patients who received intravenous nab-paclitaxel (260 mg/m
resultsTwenty-seven patients were included (median age 57.8 years; range: 35-78), 16 (59.3%) had received ≥ 3 prior chemotherapy lines; 40.7% and 59.3% had prior bevacizumab and PARP inhibitor exposure, respectively. After a median follow-up of 10 months (range: 3-40), the median PFS was 7.0 months (95% CI 5.8-8.2), with a 2-year OS rate of 57.3%. The CA125 response rate was 81.5%, with a median CA125 reduction of 70.2% (IQR 62.6-93.4), and 48.1% of patients achieved CA125 normalization. Prior chemotherapy lines, bevacizumab/PARP inhibitors exposure, and a shorter platinum-free interval did not alter the therapeutic efficacy (all P > 0.05). Among 12 patients evaluable per RECIST v1.1 criteria, the ORR was 58.3%, the median DOR was 7.0 months (95% CI 4.9-9.0), and the disease control rate was 100%. Grade 3-4 treatment-related adverse events occurred in 10 patients, mostly hematologic toxicities.
conclusionThis chemotherapy regimen demonstrated satisfactory therapeutic efficacy and manageable toxicity in heavily pretreated PROC, suggesting its potential as a viable treatment alternative.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.